April 13th
Greetings Readers,
For Monday, my full focus will be on: Artelo Biosciences, Inc. (Nasdaq: ARTL).
Artelo Biosciences, Inc. is a clinical stage pharmaceutical company dedicated to the development and commercialization of proprietary therapeutics that modulate lipid-signaling pathways including the endocannabinoid system.
Artelo is advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, anxiety, pain, neuropathy, and inflammation.
Why we're tracking it right now...
This idea involves a low float scenario. With just about 3.25Mn shares in circulation, the potential for volatile movements is considerable.
ARTL's limited share availability may have contributed to its sharp rise from a February 5th, 2025 low of $1.185 to a high of $1.5495 the next day.
That's a run of over 30% in no time!
Though nothing is guaranteed, with roughly 3.25Mn shares circulating, the potential for significant chart fluctuations may be elevated.
I'll provide more updates on (Nasdaq: ARTL) soon. Consider it for your radar and stay tuned!
Sincerely,
Kai Parker
StockWireNews
No comments:
Post a Comment